Brief: RVL Pharmaceuticals PLC Reports First Quarter 2022 Financial Results Provides Commercial Update
12/05/2022 11:59
May 12 (Reuters) - RVL Pharmaceuticals PLC RVLP.O :
* REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS; PROVIDES
COMMERCIAL UPDATE
* Q1 REVENUE $21.4 MILLION
* QTRLY LOSS PER SHARE $0.08
* COMPANY REAFFIRMS ITS GUIDANCE TARGETING NET SALES OF
UPNEEQ FOR
Q4 OF 2022 OF $20.0 TO 25.0 MILLION
* Q1 EARNINGS PER SHARE VIEW $-0.21, REVENUE VIEW $7.4
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nGNX2m52yd
Further company coverage: RVLP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius